Cargando…
A single epidermal stem cell strategy for safe ex vivo gene therapy
There is a widespread agreement from patient and professional organisations alike that the safety of stem cell therapeutics is of paramount importance, particularly for ex vivo autologous gene therapy. Yet current technology makes it difficult to thoroughly evaluate the behaviour of genetically corr...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BlackWell Publishing Ltd
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4403041/ https://www.ncbi.nlm.nih.gov/pubmed/25724200 http://dx.doi.org/10.15252/emmm.201404353 |
_version_ | 1782367305319055360 |
---|---|
author | Droz-Georget Lathion, Stéphanie Rochat, Ariane Knott, Graham Recchia, Alessandra Martinet, Danielle Benmohammed, Sara Grasset, Nicolas Zaffalon, Andrea Besuchet Schmutz, Nathalie Savioz-Dayer, Emmanuelle Beckmann, Jacques Samuel Rougemont, Jacques Mavilio, Fulvio Barrandon, Yann |
author_facet | Droz-Georget Lathion, Stéphanie Rochat, Ariane Knott, Graham Recchia, Alessandra Martinet, Danielle Benmohammed, Sara Grasset, Nicolas Zaffalon, Andrea Besuchet Schmutz, Nathalie Savioz-Dayer, Emmanuelle Beckmann, Jacques Samuel Rougemont, Jacques Mavilio, Fulvio Barrandon, Yann |
author_sort | Droz-Georget Lathion, Stéphanie |
collection | PubMed |
description | There is a widespread agreement from patient and professional organisations alike that the safety of stem cell therapeutics is of paramount importance, particularly for ex vivo autologous gene therapy. Yet current technology makes it difficult to thoroughly evaluate the behaviour of genetically corrected stem cells before they are transplanted. To address this, we have developed a strategy that permits transplantation of a clonal population of genetically corrected autologous stem cells that meet stringent selection criteria and the principle of precaution. As a proof of concept, we have stably transduced epidermal stem cells (holoclones) obtained from a patient suffering from recessive dystrophic epidermolysis bullosa. Holoclones were infected with self-inactivating retroviruses bearing a COL7A1 cDNA and cloned before the progeny of individual stem cells were characterised using a number of criteria. Clonal analysis revealed a great deal of heterogeneity among transduced stem cells in their capacity to produce functional type VII collagen (COLVII). Selected transduced stem cells transplanted onto immunodeficient mice regenerated a non-blistering epidermis for months and produced a functional COLVII. Safety was assessed by determining the sites of proviral integration, rearrangements and hit genes and by whole-genome sequencing. The progeny of the selected stem cells also had a diploid karyotype, was not tumorigenic and did not disseminate after long-term transplantation onto immunodeficient mice. In conclusion, a clonal strategy is a powerful and efficient means of by-passing the heterogeneity of a transduced stem cell population. It guarantees a safe and homogenous medicinal product, fulfilling the principle of precaution and the requirements of regulatory affairs. Furthermore, a clonal strategy makes it possible to envision exciting gene-editing technologies like zinc finger nucleases, TALENs and homologous recombination for next-generation gene therapy. |
format | Online Article Text |
id | pubmed-4403041 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | BlackWell Publishing Ltd |
record_format | MEDLINE/PubMed |
spelling | pubmed-44030412015-04-23 A single epidermal stem cell strategy for safe ex vivo gene therapy Droz-Georget Lathion, Stéphanie Rochat, Ariane Knott, Graham Recchia, Alessandra Martinet, Danielle Benmohammed, Sara Grasset, Nicolas Zaffalon, Andrea Besuchet Schmutz, Nathalie Savioz-Dayer, Emmanuelle Beckmann, Jacques Samuel Rougemont, Jacques Mavilio, Fulvio Barrandon, Yann EMBO Mol Med Research Articles There is a widespread agreement from patient and professional organisations alike that the safety of stem cell therapeutics is of paramount importance, particularly for ex vivo autologous gene therapy. Yet current technology makes it difficult to thoroughly evaluate the behaviour of genetically corrected stem cells before they are transplanted. To address this, we have developed a strategy that permits transplantation of a clonal population of genetically corrected autologous stem cells that meet stringent selection criteria and the principle of precaution. As a proof of concept, we have stably transduced epidermal stem cells (holoclones) obtained from a patient suffering from recessive dystrophic epidermolysis bullosa. Holoclones were infected with self-inactivating retroviruses bearing a COL7A1 cDNA and cloned before the progeny of individual stem cells were characterised using a number of criteria. Clonal analysis revealed a great deal of heterogeneity among transduced stem cells in their capacity to produce functional type VII collagen (COLVII). Selected transduced stem cells transplanted onto immunodeficient mice regenerated a non-blistering epidermis for months and produced a functional COLVII. Safety was assessed by determining the sites of proviral integration, rearrangements and hit genes and by whole-genome sequencing. The progeny of the selected stem cells also had a diploid karyotype, was not tumorigenic and did not disseminate after long-term transplantation onto immunodeficient mice. In conclusion, a clonal strategy is a powerful and efficient means of by-passing the heterogeneity of a transduced stem cell population. It guarantees a safe and homogenous medicinal product, fulfilling the principle of precaution and the requirements of regulatory affairs. Furthermore, a clonal strategy makes it possible to envision exciting gene-editing technologies like zinc finger nucleases, TALENs and homologous recombination for next-generation gene therapy. BlackWell Publishing Ltd 2015-04 2015-02-27 /pmc/articles/PMC4403041/ /pubmed/25724200 http://dx.doi.org/10.15252/emmm.201404353 Text en © 2015 The Authors. Published under the terms of the CC BY 4.0 license http://creativecommons.org/licenses/by/4.0/ This is an open access article under the terms of the Creative Commons Attribution 4.0 License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Articles Droz-Georget Lathion, Stéphanie Rochat, Ariane Knott, Graham Recchia, Alessandra Martinet, Danielle Benmohammed, Sara Grasset, Nicolas Zaffalon, Andrea Besuchet Schmutz, Nathalie Savioz-Dayer, Emmanuelle Beckmann, Jacques Samuel Rougemont, Jacques Mavilio, Fulvio Barrandon, Yann A single epidermal stem cell strategy for safe ex vivo gene therapy |
title | A single epidermal stem cell strategy for safe ex vivo gene therapy |
title_full | A single epidermal stem cell strategy for safe ex vivo gene therapy |
title_fullStr | A single epidermal stem cell strategy for safe ex vivo gene therapy |
title_full_unstemmed | A single epidermal stem cell strategy for safe ex vivo gene therapy |
title_short | A single epidermal stem cell strategy for safe ex vivo gene therapy |
title_sort | single epidermal stem cell strategy for safe ex vivo gene therapy |
topic | Research Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4403041/ https://www.ncbi.nlm.nih.gov/pubmed/25724200 http://dx.doi.org/10.15252/emmm.201404353 |
work_keys_str_mv | AT drozgeorgetlathionstephanie asingleepidermalstemcellstrategyforsafeexvivogenetherapy AT rochatariane asingleepidermalstemcellstrategyforsafeexvivogenetherapy AT knottgraham asingleepidermalstemcellstrategyforsafeexvivogenetherapy AT recchiaalessandra asingleepidermalstemcellstrategyforsafeexvivogenetherapy AT martinetdanielle asingleepidermalstemcellstrategyforsafeexvivogenetherapy AT benmohammedsara asingleepidermalstemcellstrategyforsafeexvivogenetherapy AT grassetnicolas asingleepidermalstemcellstrategyforsafeexvivogenetherapy AT zaffalonandrea asingleepidermalstemcellstrategyforsafeexvivogenetherapy AT besuchetschmutznathalie asingleepidermalstemcellstrategyforsafeexvivogenetherapy AT saviozdayeremmanuelle asingleepidermalstemcellstrategyforsafeexvivogenetherapy AT beckmannjacquessamuel asingleepidermalstemcellstrategyforsafeexvivogenetherapy AT rougemontjacques asingleepidermalstemcellstrategyforsafeexvivogenetherapy AT maviliofulvio asingleepidermalstemcellstrategyforsafeexvivogenetherapy AT barrandonyann asingleepidermalstemcellstrategyforsafeexvivogenetherapy AT drozgeorgetlathionstephanie singleepidermalstemcellstrategyforsafeexvivogenetherapy AT rochatariane singleepidermalstemcellstrategyforsafeexvivogenetherapy AT knottgraham singleepidermalstemcellstrategyforsafeexvivogenetherapy AT recchiaalessandra singleepidermalstemcellstrategyforsafeexvivogenetherapy AT martinetdanielle singleepidermalstemcellstrategyforsafeexvivogenetherapy AT benmohammedsara singleepidermalstemcellstrategyforsafeexvivogenetherapy AT grassetnicolas singleepidermalstemcellstrategyforsafeexvivogenetherapy AT zaffalonandrea singleepidermalstemcellstrategyforsafeexvivogenetherapy AT besuchetschmutznathalie singleepidermalstemcellstrategyforsafeexvivogenetherapy AT saviozdayeremmanuelle singleepidermalstemcellstrategyforsafeexvivogenetherapy AT beckmannjacquessamuel singleepidermalstemcellstrategyforsafeexvivogenetherapy AT rougemontjacques singleepidermalstemcellstrategyforsafeexvivogenetherapy AT maviliofulvio singleepidermalstemcellstrategyforsafeexvivogenetherapy AT barrandonyann singleepidermalstemcellstrategyforsafeexvivogenetherapy |